You are here: Industry Insights > boehringer

News List

Lilly, Boehringer's Jardiance bags FDA approval for heart failure firstwordpharma
August 19, 2021
The FDA has expanded the label for Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) to include reducing the risk of cardiovascular death plus hospitalisation for heart failure (HF) in adult patients with reduced ejection fraction (HFrEF).
Novatek Requalified as Supplier for Boehringer Aseptic Mfg. Facilities contractpharma
May 27, 2021
Novatek's regulatory compliant quality solutions used at Boehringer for human pharma, animal health and biopharmaceutical sterile manufacturing sites.
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction contractpharma
December 11, 2020
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.
Bridge Biotherapeutics terminates collaboration agreement with Boehringer pharmaceutical-technology
November 11, 2020
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877.
EC approves new indication for Boehringer’s nintedanib in pulmonary fibrosis pharmaceutical-business-review
July 17, 2020
Boehringer Ingelheim has secured approval for a new indication of nintedanib to treat adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).
Boehringer to sell stake in Hikma pharmatimes
June 24, 2020
Boehringer Ingelheim Invest has announced plans to pull its investment in Hikma Pharmaceuticals.
Boehringer and CDR-Life to develop geographic atrophy therapies pharmaceutical-technology
May 15, 2020
Boehringer Ingelheim has signed a collaboration and licensing agreement with CDR-Life for the research and development of antibody fragment-based therapeutics to treat geographic atrophy (GA).
Insilico and Boehringer to use AI for drug targets discovery pharmaceutical-technology
April 16, 2020
Boehringer partners Insilico for AI-based discovery of drug targets. Insilico Medicine has partnered with Boehringer Ingelheim.
FDA hands Boehringer and Lilly complete response letter for insulin adjunct March 26, 2020
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
Boehringer, Lilly Get Complete Response Letter for Empagliflozin contractpharma
March 24, 2020
FDA is unable to approve sNDA for Empagliflozin in type 1 diabetes.

Previous page 1 2 3 4 5 6 Next page